Korean molecular diagnostic company Gencurix Inc reported on Wednesday that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test, a diagnostic kit for COVID-19.
This is the second RT-PCR test launched by Gencurix following its first test assay, GenePro COVID-19 Detection Test, which was released in March.
Advantages of the GenePro SARS-CoV-2 Test include simultaneous monitoring of up to 384 samples, allowing high throughput screening of the novel coronavirus.
With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests across the United States.
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch